rs1800547 — MAPT H1/H2 Haplotype Splice Regulator

MAPT rs1800547 — The Molecular Switch in Tau's H1/H2 Divide

Within the microtubule-associated protein tau (MAPT) gene on chromosome 17q21, a single nucleotide difference at rs1800547 marks one of the most consequential forks in human neurological risk: the ancient H1/H2 haplotype boundary. While the broader H1/H2 distinction spans a 900-kilobase chromosomal inversion, rs1800547 is the canonical SNP that directly differentiates the H1 and H2 clades¹¹ canonical SNP that directly differentiates the H1 and H2 clades
The GenePD Study found rs1800547 was the single most statistically significant variant in the region for Parkinson's disease after multiple testing correction. Unlike rs17649553, which is another H1/H2 tag in the region, rs1800547 has been shown to have direct molecular function — not merely a passive marker of haplotype membership.

The MAPT gene produces tau, a protein whose primary job is stabilizing the neuronal microtubule skeleton and supporting axonal transport. When tau becomes hyperphosphorylated and misfolds, it aggregates into neurofibrillary tangles, the pathological hallmark of tauopathies including Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).

The Mechanism: Splice Factor Binding and Exon 3

A landmark 2017 study using whole-locus MAPT expression vectors demonstrated that rs1800547, working together with rs17651213, directly controls haplotype-specific inclusion of MAPT exon 3²² A landmark 2017 study using whole-locus MAPT expression vectors demonstrated that rs1800547, working together with rs17651213, directly controls haplotype-specific inclusion of MAPT exon 3
Exon 3 encodes a region of the N-terminal projection domain of tau that affects its interaction with membranes and the neuronal cytoskeleton. Using electrophoretic mobility shift assays, researchers found that the H1 (A) and H2 (G) alleles at rs1800547 create distinct RNA-protein binding patterns with splicing factors hnRNP F and hnRNP Q — critical regulators of alternative splicing in neurons. The H2 sequence at this position allows 1.76-fold higher exon 3 inclusion compared to H1, altering the proportion of N1 and N2 tau isoforms.

This matters because the balance of tau isoforms — not just total tau levels — appears critical to which tauopathy, if any, develops. H1 is associated with elevated 4-repeat (4R) tau isoforms, which are the primary constituents of pathological aggregates in PSP and CBD. H2's different splicing pattern may shift the balance away from aggregation-prone 4R isoforms.

The Evidence for Parkinson's Disease

The GenePD Study genotyped 21 SNPs across the MAPT region in PD families and controls, finding that rs1800547 emerged as the most statistically significant variant for PD association, surviving multiple testing correction³³ The GenePD Study genotyped 21 SNPs across the MAPT region in PD families and controls, finding that rs1800547 emerged as the most statistically significant variant for PD association, surviving multiple testing correction
The study also found 4-repeat MAPT isoforms significantly elevated in PD brains (p=0.002), linking the H1 splicing signature to disease pathology. A large case-control study of 1,762 PD patients and 2,010 controls found that H1/H1 homozygotes had an odds ratio of 1.46 (95% CI 1.25–1.69, p=8×10⁻⁷) for PD compared to H1/H2 and H2/H2 carriers⁴⁴ 1,762 PD patients and 2,010 controls found that H1/H1 homozygotes had an odds ratio of 1.46 (95% CI 1.25–1.69, p=8×10⁻⁷) for PD compared to H1/H2 and H2/H2 carriers
The association held across familial and sporadic disease, both sexes, and early- and late-onset subgroups.

Progressive Supranuclear Palsy: The Strongest Association

The H1/H1 genotype is found in approximately 94% of PSP patients compared to ~64% of the general population — a striking enrichment. A JAMA Neurology study of 802 neuropathologically confirmed PSP cases identified H1 subhaplotypes with markedly elevated risk: H1d (OR 1.86), H1g (OR 3.64), and H1o (OR 2.60)⁵⁵ 802 neuropathologically confirmed PSP cases identified H1 subhaplotypes with markedly elevated risk: H1d (OR 1.86), H1g (OR 3.64), and H1o (OR 2.60)
These sub-haplotype associations suggest that specific combinations of H1-background variants, on top of the rs1800547 A allele, determine the magnitude of PSP risk. The chromosome 17q21.31 region — anchored by rs1800547 — represents the single strongest genetic risk locus for PSP identified to date.

Alzheimer's Disease: A Different Pathway

A study of 17,996 participants (8,559 AD cases, 9,437 controls) across Spanish and international cohorts found that rs1800547 itself was associated with AD risk (OR 1.12, p=0.0025)⁶⁶ A study of 17,996 participants (8,559 AD cases, 9,437 controls) across Spanish and international cohorts found that rs1800547 itself was associated with AD risk (OR 1.12, p=0.0025)
The effect was strongest in APOE ε4 non-carriers — suggesting MAPT H1 represents an alternative causal pathway to AD distinct from amyloid-driven disease. The risk was highest in individuals over age 77 without APOE ε4 (p=0.001), suggesting a late-life tau-driven pathway independent of beta-amyloid accumulation. For people without the APOE ε4 allele, the MAPT H1 haplotype tagged by rs1800547 becomes a more prominent contributor to AD risk.

ALS and Frontotemporal Spectrum

Beyond the primary tauopathies, a 2023 study of Bulgarian ALS patients found the H1b subhaplotype (containing the rs1800547 A allele) conferred a nearly 2-fold increased risk for sporadic ALS⁷⁷ a 2023 study of Bulgarian ALS patients found the H1b subhaplotype (containing the rs1800547 A allele) conferred a nearly 2-fold increased risk for sporadic ALS
The authors propose that fine transcriptional regulation at the MAPT locus, including rs1800547's splice factor interactions, may influence ALS susceptibility through shared tau biology with FTD. ALS and FTD share genetic and pathological overlap, and MAPT variation may contribute to the clinical spectrum between them.

Practical Actions

For H1/H1 carriers (AA genotype), the relevant clinical considerations are monitoring for motor symptoms that might indicate early parkinsonism, PSP, or CBD — conditions where early specialist evaluation matters for accurate diagnosis and prognosis. PSP in particular is frequently misdiagnosed as Parkinson's disease but responds differently to treatment. For the Alzheimer's disease risk — especially relevant for APOE ε4 non-carriers — knowing your MAPT status can help contextualize the late-life cognitive monitoring picture.

There are currently no approved pharmacological agents specifically targeting MAPT splicing or H1-driven tau isoform imbalance, though several anti-tau therapies are in clinical trials. Lifestyle factors — particularly aerobic exercise and head trauma prevention — have independent evidence for neuroprotection across multiple pathways relevant to tauopathy risk.

Interactions

rs1800547 and rs17649553 both tag the same H1/H2 haplotype and are in very strong linkage disequilibrium. If a person's genome contains both SNPs, their results should be concordant. The H1 risk at this locus compounds with rs356182 (SNCA) for Parkinson's disease risk — though interaction analyses have found these act independently rather than epistatically. In Alzheimer's disease, the H1/H2 distinction interacts with APOE genotype (rs429358), with H1 risk most pronounced in APOE ε4 non-carriers.